Increase in prevalence of rare and genetic disorders including muscular dystrophy, cystic fibrosis, spina bifida, and others and surge in demand for personalized medicine drive the growth of the global rare biomarkers specimen collection and stabilization market.
PORTLAND , Ore. , Oct. 7, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Rare Biomarkers Specimen Collection and Stabilization Market by Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes Vesicles), by Product (Isolation Kits and Reagent, Blood Collection Tubes, Systems), by Application (Oncology, Cardiovascular Diseases, NIPT, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global rare biomarkers specimen collection and stabilization industry generated $23.3 billion in 2021, and is expected to reach $54.2 billion by 2031, witnessing a CAGR of 8.7% from 2022 to 2031.
Download Free Sample Report- https://www.alliedmarketresearch.com/request-sample/13595
Prime determinants of growth Increase in prevalence of rare and genetic disorders including muscular dystrophy, cystic fibrosis, spina bifida, and others, rise in preference for minimally non-invasive mode of disease treatment, and surge in demand for personalized medicine drive the growth of the global rare biomarkers specimen collection and stabilization market. However, the tedious and lengthy process for development of biomarkers and high cost of the development restrain the market growth. On the other hand, emerging healthcare infrastructure in developing countries, rise in applications of rare biomarker specimens in pharmacogenomics, and surge in risks of pandemic and rare genetic diseases present new opportunities in the coming years.
The Covid-19 pandemic made a positive impact on the global rare biomarkers specimen collection and stabilization market, owing to surge in prevalence of rare diseases and innovations in diagnosis of diseases using biomarkers. In addition, the demand for isolation kits and reagents increased considerably.
On-time diagnosis and hospitalization, utilization of intensive care services, risk stratification, selection of correct therapies, and monitoring and timely discharge are essential for saving the maximum number of lives. Laboratory markers or biomarkers offered additional and objective information that can significantly impact the components of patient care.
Rare biomarkers specimen collection and stabilization are utilized for determining what the coronavirus does to the body and how the body reacts on infection. This, in turn, will increase the revenue of the market.
The circulating cell free DNA (ccfDNA) segment to maintain its leadership position throughout the forecast period
Based on type, the circulating cell free DNA (ccfDNA) segment accounted for the largest market share in 2021, contributing to more than two-fifths of the global rare biomarkers specimen collection and stabilization market, and is estimated to maintain its leadership position throughout the forecast period. Moreover, this segment is expected to register the highest CAGR of 9.5% from 2022 to 2031. This is attributed to increase in adoption of NIPT in detecting chromosomal anomalies in the fetus and utilization of ccfDNA as tumor biomarker for cancer diagnosis and monitoring, prognosis assessment, and personalized medication guidance. The report provides a detailed analysis of segments including circulating tumor cells (CTCs) and exosomes vesicles.
The isolation kits and reagent segment to continue its leadership status throughout the forecast period Based on product, the isolation kits and reagent segment contributed to the highest market share in 2021, accounting for more than two-fifths of the global rare biomarkers specimen collection and stabilization market, and will continue its leadership in terms of revenue throughout the forecast period. Moreover, this segment is estimated to manifest the largest CAGR of 9.4% from 2022 to 2031. This is attributed to rise in prevalence of cancer & rare genetic disorder and surge in investments in exploring the utility of CTCs in diagnosis, prognosis, and treatment monitoring. The research also discusses segments including blood collection tubes and systems.
Having any Query, Let's connect to Our Analyst- https://www.alliedmarketresearch.com/purchase-enquiry/13595
The oncology segment to continue its highest contribution throughout the forecast period Based on application, the oncology segment accounted for the largest market share in 2021, holding nearly one-fourth of the global rare biomarkers specimen collection and stabilization market, and is estimated to continue its highest contribution throughout the forecast period. Moreover, this segment is projected to grow at the fastest CAGR of 10.2% from 2022 to 2031. This is due to advancements in technology, interest in personalized medication, rapid expansion of precision medicine in oncology, and increase in prevalence of cancer cases. The report also analyzes the segments including cardiovascular diseases, NIPT, transcriptomics, pharmacogenomics, transplant rejection, population screening, and others.
North America to continue its dominant share throughout the forecast period Based on region, North America held the largest market share in 2021, accounting for around two-fifths of the global rare biomarkers specimen collection and stabilization market, and is projected to continue its dominant share throughout the forecast period. This is attributed to rise in prevalence of chronic and genetic diseases, surge in healthcare expenditure, and increase in number of approved rare biomarker isolation kits for clinical and research use. However, Asia-Pacific is estimated to witness at the fastest CAGR of 9.8% from 2022 to 2031. This is due to presence of high unmet medical needs, constantly improving healthcare infrastructure to cure chronic disorders, and rise in investments for exploring the utility of circulating tumor cells (CTCs) in diagnosis, prognosis, and treatment monitoring.
F. Hoffman La Roche AG
Similar Research Reports for Information, Communication and Technology:
Intraoperative Imaging Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
Dermatologicals Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
3D Cell Culture Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
Neurovascular Devices Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
Viral Vector and Plasmid DNA Manufacturing Market- Global Opportunity Analysis and Industry Forecast, 2021–2030
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model): AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon . Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free: 1-800-792-5285 UK: +44-845-528-1300 Hong Kong : +852-301-84916 India (Pune ): +91-20-66346060 Fax: +1-855-550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com
Logo - https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/rare-biomarkers-specimen-collection-and-stabilization-market-to-reach-usd-54-2-billion-globally-by-2031-at-8-7-cagr-allied-market-research-301643807.html
Shares of enterprise software companies Twilio (NYSE: TWLO), Snowflake (NYSE: SNOW), and Appian (NASDAQ: APPN) fell hard again Monday, down 6.3%, 9.3%, and 6.5%, respectively, as of 3:44 p.m. EDT. In addition, long-term bond yields remained high. On Monday, cloud-based service-center software company Five9 (NASDAQ: FIVN) plunged over 25%, after CEO Rowan Trollope announced he would be resigning for another role at a pre-IPO tech company.
Billionaire hedge-fund investor Paul Tudor Jones says investors looking to time the bottom in stocks should keep a close eye on short-term Treasury yields.
In this article, we discuss 5 dividend stocks that are too cheap to ignore. You can skip our detailed analysis of dividend stocks and their returns in the past, and go directly to read 5 Dividend Stocks That Are Too Cheap To Ignore. As the market plunges to its new lows in 2022, investors are […]
After the annus horribilis of 2022, with the final quarter now in play, investors will be hoping a late-year rally will materialize. According to Carson Group's chief market strategist Ryan Detrick, that’s not such a far-fetched idea. "While October has a reputation for crashes, it is really a bear market killer,” Detrick recently wrote. “Of the past 17 bear (or near bear markets), stocks bottomed in October six times. Could it happen again? With sentiment this pessimistic and extremely positive
Yahoo Finance's Alexandra Semenova breaks down what to watch from big banks as they're set to release earnings this week.
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Pfizer Inc. (PFE) and Citigroup Inc. (C).
Does the October share price for Lumen Technologies, Inc. ( NYSE:LUMN ) reflect what it's really worth? Today, we will...
Yahoo Finance Live anchors discuss stock performance for PayPal as well as why the financial tech company is backtracking on its misinformation policy.
A Cowen analyst says chip stocks are near all-time low valuations after their big drops this year. Several offer solid buying opportunities.
Ford stock and General Motors stock both fell Monday morning after analysts cut their price targets and downgraded ratings.
It was yet another difficult day for automotive investors. This morning, share prices of Ford (NYSE: F) and General Motors (NYSE: GM) were sliding after a UBS analyst downgraded the automotive stocks. Nio (NYSE: NIO) investors weren't having much of a better morning either, as the Chinese automaker's stock was falling likely on news that fellow EV maker Rivian issued a significant recall of most of its vehicles.
Shares of Ford Motor Co. were hit hard Monday by UBS analyst Patrick Hummel's recommendation that investors sell, as the auto industry is facing a worrisome U-turn from undersupply to oversupply.
Intel (NASDAQ: INTC) has been under tremendous pressure this year. Shares of the semiconductor company have tumbled about 50%. While Intel is facing its share of headwinds, I believe better days lie ahead for the tech giant and its big-time dividend.
(Bloomberg) -- Everywhere you turn, the biggest players in the $23.7 trillion US Treasuries market are in retreat.Most Read from BloombergHere’s How Weird Things Are Getting in the Housing MarketScreening Procedure Fails to Prevent Colon Cancer Deaths in Large StudyThis Is What 7% Mortgages Will Do to the Housing MarketPutin Threatens More Missile Attacks on Ukraine as Cities HitCathie Wood Warns of ‘Serious Losses’ in Automobile DebtFrom Japanese pensions and life insurers to foreign government
In this article, we discuss 10 best hydrogen and fuel cell stocks to buy in 2022. If you want to read about some more hydrogen and fuel cell stocks, go directly to 5 Best Hydrogen and Fuel Cell Stocks to Buy in 2022. The hydrogen and fuel cell market has come under increased media spotlight […]
Intel (INTC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Oil prices have bounced around quite a bit this year. Brent oil, the global-pricing benchmark, started 2022 below $80 a barrel before soaring into the $120s following Russia's invasion of Ukraine. With the prospect of higher oil prices, we asked some of our energy contributors what oil stocks they believe are best positioned to capitalize following OPEC's bold move.
Each month I buy several dividend stocks to help build my passive income stream toward my goal of having it eventually offset my expenses. This October, I plan to add to my positions in Blackstone Group (NYSE: BX), Clearway Energy (NYSE: CWEN)(NYSE: CWEN.A), Digital Realty (NYSE: DLR), Realty Income (NYSE: O), and NextEra Energy (NYSE: NEE) as more cash flows into my portfolio.
The company's longtime CEO announced his retirement, leading some analysts to contemplate a cut to the 14% dividend.
Microsoft (MSFT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.